Japan Based Daiichi Sankyo Company, Limited Announced That It Has Entered Into A Clinical Trial Collaboration Agreement With A Subsidiary Of Merck &Amp; Co., Inc., Kenilworth, New Jersey, U.S.A., Known As Msd Outside The United States And Canada, To Evaluate The Combination Of Ds-1062, A Trop2 Directed Dxd Antibody Drug Conjugate (Adc), And Keytruda&Reg; (Pembrolizumab) In Patients With Previously-Treated Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Without Actionable Genomic Alterations.Trop2 (Trophoblast Cell-Surface Antigen 2) Is A Transmembrane Glycoprotein That Is Overexpressed In Many Cancers; High Trop2 Expression Has Been Identified In A Majority Of Nsclcs.Under The Terms Of The Agreement, Daiichi Sankyo Will Conduct A Multicenter, Two-Part, Open-Label, Non-Randomized, Phase 1B Study Of Ds-1062 In Combination With Keytruda In Patients With Advanced Or Metastatic Nsclc Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Immunotherapy.Ds-1062 Is One Of Three Lead Dxd Antibody Drug Conjugates (Adcs) In The Oncology Pipeline Of Daiichi Sankyo.
